Welcome to our dedicated page for Genprex SEC filings (Ticker: GNPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genprex, Inc. (NASDAQ: GNPX) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission disclosures, along with AI-assisted context. As a clinical-stage gene therapy company, Genprex uses these filings to describe its oncology and diabetes pipelines, financing activities, and Nasdaq listing status.
Key documents include registration statements such as Form S-1 and Form S-3, where Genprex outlines its business overview, risk factors, and details of equity offerings and warrant structures. These filings describe the company’s focus on Reqorsa Gene Therapy (quaratusugene ozeplasmid) for non-small cell and small cell lung cancer, the Oncoprex Delivery System, and the GPX-002 diabetes gene therapy program using AAV delivery of Pdx1 and MafA genes to the pancreas.
Investors can also review Form 8-K current reports that document material events. Recent 8-Ks discuss registered direct offerings and concurrent private placements, at-the-market program updates, new patents and patent intentions around Reqorsa combinations with PD-1 and PD-L1 antibodies, additions of clinical trial sites for Acclaim-1 and Acclaim-3, and communications with Nasdaq regarding minimum bid price and stockholders’ equity requirements.
On Stock Titan, AI-powered tools summarize lengthy prospectuses and current reports, helping readers quickly identify sections related to gene therapy mechanisms, clinical trial design, regulatory designations, and capital-raising terms. As new filings appear on EDGAR, they are reflected here in near real time, giving users an organized view of Genprex’s regulatory history, financing transactions, and disclosures relevant to GNPX stock.
Genprex, Inc. filed a report describing a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to its Reqorsa Gene Therapy for non-small cell and small cell lung cancer.
The company also highlights progress in its Acclaim-1 and Acclaim-3 Phase 1/2 trials combining Reqorsa with Tagrisso and Tecentriq. Early Phase 1 data showed no dose limiting toxicities and signals of efficacy, including prolonged progression free survival and partial remissions in individual patients who continue on treatment.
Genprex, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 18, 2026, where stockholders will vote on director elections, ratification of WithumSmith+Brown, PC as auditor, an advisory vote on executive compensation, approval of an amended 2018 Equity Incentive Plan, and a proposed reverse stock split at a ratio between 1:5 and 1:50 (to be implemented at the Board’s discretion any time prior to December 31, 2027).
The record date for voting is April 24, 2026. The proxy materials, including the Company’s 2025 Annual Report on Form 10-K, will be mailed beginning on or about April (date omitted). The Board recommends voting FOR the named director nominees and the listed proposals.
Genprex, Inc. director Brent M. Longnecker reported small open-market sales of Genprex common stock, primarily for tax purposes. On April 14, 2026, he sold 8 shares of common stock at $1.23 per share from his direct holdings and 10 shares at $1.23 per share through indirect ownership by Longnecker Associates Ltd. Following these transactions, he directly holds 9,157 shares of Genprex common stock, with no remaining indirect shares reported in this filing.
Genprex, Inc. is a clinical-stage gene therapy company developing REQORSA for lung cancer and GPX-002 for Type 1 and Type 2 diabetes. REQORSA, delivered with the non-viral ONCOPREX system, is in Phase 2a Acclaim-1 for EGFR-mutant NSCLC and Phase 2 Acclaim-3 for extensive-stage small cell lung cancer, both with FDA Fast Track status and Orphan Drug Designation in SCLC.
The company is advancing preclinical GPX-002 diabetes programs after an FDA meeting in February 2026 on IND-enabling studies. Genprex strengthened liquidity via an at-the-market program, raising about $10.8 million in 2025 and $13.3 million through early 2026, executed two reverse stock splits to support Nasdaq listing, and regained compliance with Nasdaq equity and bid price rules. As of March 27, 2026, it had 9,044,856 common shares outstanding and a non-affiliate equity market value of about $7.5 million as of June 30, 2025.
Genprex, Inc. reported that its research collaborators will present three posters at the 2026 AACR Annual Meeting featuring new preclinical data on its lead candidate, REQORSA (quaratusugene ozeplasmid, “Quar Oze”), for non-small cell lung cancer.
The first study identifies TROP2 and PTEN expression patterns as potential biomarkers of primary resistance to TUSC2 gene therapy across NSCLC cell lines, organoids and xenograft models, helping explain which tumors may not respond.
The second study shows Quar Oze-driven TUSC2 overexpression induces strong tumor cell death in ALK-positive NSCLC models and enhances the effect of the ALK inhibitor alectinib, including in alectinib-resistant tumors, with combination treatment achieving the greatest tumor shrinkage and survival benefits in mice.
The third study demonstrates that restoring TUSC2 via Quar Oze boosts natural killer (NK) cell cytotoxicity, improves antitumor immune responses and, in many cases, leads to complete tumor regression in mouse models, supporting TUSC2 as both a tumor suppressor and immunomodulatory target.
Genprex, Inc.’s Chief Medical Officer, Mark Stanley Berger, reported a tax-related share withholding. On February 27, 2026, 7,168 shares of common stock were withheld to cover tax obligations tied to the vesting of Restricted Stock Units granted under Genprex’s 2018 Equity Incentive Plan. After this tax-withholding disposition, he directly owned 21,692 shares of Genprex common stock.
Genprex, Inc. director and executive officer Ryan M. Confer reported a Form 4 transaction showing a tax-withholding disposition of 9,330 shares of common stock at $2.00 per share. According to the disclosure, these shares were withheld on February 27, 2026 to satisfy tax withholding obligations tied to vesting restricted stock units granted under the company’s 2018 Equity Incentive Plan. After this withholding, Confer directly holds 36,331 shares of Genprex common stock.
Genprex, Inc. reported that the Japanese Patent Office issued a favorable appeal decision to grant a patent covering use of REQORSA Gene Therapy with PD‑L1 antibodies to treat cancer, and the European Patent Office issued a decision to grant a patent for REQORSA in combination with PD‑1 antibodies. Genprex holds an exclusive license to these patents and states they strengthen protection for therapeutic combinations, including its Acclaim‑3 trial in small cell lung cancer.
The company notes it already has granted patents for REQORSA and PD‑L1 combinations in the U.S. and Korea, with a pending grant in Australia, and REQORSA and PD‑1 combinations in multiple regions including the U.S., Japan and the EU. Acclaim‑3 is a Phase 1/2 trial of REQORSA plus Genentech’s Tecentriq as maintenance therapy for extensive‑stage small cell lung cancer. The Phase 2 expansion is expected to enroll about 50 patients, with an interim analysis planned after the 25th patient has 18 weeks of follow‑up. Genprex expects to complete enrollment of the first 25 patients in the first half of 2026 and conduct the interim analysis in the second half of 2026. The trial has U.S. FDA Fast Track and Orphan Drug designations.
Genprex, Inc. received a Schedule 13G showing that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri together report beneficial ownership of 249,788 shares of Genprex common stock through warrants. This position represents 9.72% of the common stock, calculated using 2,318,894 shares outstanding as of November 19, 2025, plus the warrant shares. The warrants are subject to a 9.99% beneficial ownership blocker, limiting how many shares can be issued on exercise at any time. The investors certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Genprex.
Genprex, Inc. reported that IP Australia issued a Notice of Acceptance for its patent application covering the use of REQORSA Gene Therapy with PD-L1 antibodies to treat cancers. If granted, this patent would secure exclusivity for this drug combination in Australia and strengthen Genprex’s intellectual property portfolio alongside granted patents in the U.S. and Korea.
The company is also pursuing additional patent applications in Europe, Canada, Brazil, China and Israel and has opened a new Acclaim-3 clinical trial site at the University of Kentucky. Acclaim-3 is a Phase 1/2 trial of REQORSA plus Tecentriq as maintenance therapy for extensive stage small cell lung cancer, supported by FDA Fast Track and Orphan Drug Designations.
The Phase 2 expansion is expected to enroll about 50 patients, with an interim analysis planned after the 25th patient reaches 18 weeks of follow-up. Genprex expects to complete enrollment of these 25 patients in the first half of 2026 and conduct the interim analysis in the second half of 2026.